N	Concordance
1	 d with induction chemotherapy with ADE (cytarabine, daunorubicin, etoposide) vs
2	 patients who  received high dose bolus cytarabine at a single institution, the 
3	 in vitro, their modulation of cellular cytarabine (ARA-C) metabolism and enhanc
4	 abine/etoposide) vs. DCE (daunorubicin/cytarabine/etoposide) in patients with n
5	f mitoxantrone  combined with high-dose cytarabine as induction therapy in patie
6	hemotherapy combining intermediate-dose cytarabine and amsacrine. Patients with 
7	oxyurea (HU) (19 patients), or low-dose cytarabine (Ara-C) (67 patients). Overal
8	diagnosis. The CR rate to standard-dose cytarabine and daunorubicin was similar 
9	n administered as a continuous infusion cytarabine causes profound myelosuppress
10	 AlBM;  with, as indicated, Intrathecal Cytarabine, IT ARA-C, NSC-63878.        
11	  effects and tolerability of liposomal cytarabine (Depofoam encapsulated cytara
12	 ost remission chemotherapy consists of cytarabine IV given as a 5 day continuou
13	 tandard therapy receive unencapsulated cytarabine injection twice every 7 days 
14	rall  survival following induction with cytarabine/mitoxantrone (ARA-C/DHAD),  i